Status:

NOT_YET_RECRUITING

DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

Lead Sponsor:

Nuravax, Inc.

Collaborating Sponsors:

National Institute on Aging (NIA)

Institute for Molecular Medicine

Conditions:

Alzheimer Disease

Alzheimer Disease (AD)

Eligibility:

All Genders

40-65 years

Phase:

PHASE1

Brief Summary

This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramu...

Detailed Description

This is a first-in-human, randomized, double-blind, placebo-controlled Phase 1 trial of DUVAX, an adjuvanted vaccine, in up to 24 healthy participants aged 40-65 years. Two dose levels (200 µg and 400...

Eligibility Criteria

Inclusion

  • Healthy males and non-pregnant, non-lactating females, 40-65 years old
  • BMI between 18.0 and 32.0 kg/m²
  • Medically healthy with no significant abnormalities in medical history, exam, labs, ECG, or MRI
  • Signed informed consent
  • Women of childbearing potential: negative pregnancy test and use of effective contraception
  • Men: vasectomized or agree to use condoms / not donate sperm during the study period

Exclusion

  • Clinically significant medical or psychiatric illness that may affect safety or study results
  • MRI abnormalities (e.g., infarcts, microbleeds, ARIA-E) or contraindications to MRI
  • Significant lab abnormalities (e.g., liver, kidney, hematology) or positive HIV/HBV/HCV tests
  • Uncontrolled blood pressure, abnormal heart rate, or prolonged QTc interval
  • Recent serious illness, surgery, or investigational drug use within 30 days
  • Prior amyloid-beta or tau immunotherapy within 1 year
  • Use of immunosuppressive agents or chronic anticoagulants
  • History of severe vaccine reactions, autoimmune disease, or significant allergies

Key Trial Info

Start Date :

November 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 31 2027

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT07142278

Start Date

November 1 2025

End Date

July 31 2027

Last Update

October 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Palm Springs Community Health Center

Miami Lakes, Florida, United States, 33014